End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.71 CNY | -0.88% | +2.94% | -37.43% |
Apr. 26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
Apr. 25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.43% | 3.25B | |
-3.79% | 87.06B | |
+2.76% | 40.25B | |
-17.49% | 31.09B | |
+54.69% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+4.94% | 8.73B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Walvax Biotech to Push Through with Phase Three Study of New COVID Vaccine